TGBA01AD

From Wikipedia, the free encyclopedia
Jump to: navigation, search
TGBA01AD
Clinical data
Routes of
administration		 Oral
Pharmacokinetic data
Bioavailability 17%[1]
Biological half-life 4 hours[2]
Identifiers
Synonyms FKB01MD

TGBA01AD (also known as FKB01MD) is a serotonin reuptake inhibitor, 5-HT1A and 5-HT1D receptor agonist, and 5-HT2 receptor antagonist which is under development by Fabre-Kramer for the treatment of major depressive disorder.[1] [2] It has been in phase II clinical trials since 2009, and as of January 2016, remains in this phase of development.[3]

See also[edit]

References[edit]

  1. ^ "Drugs in Clinical Development for Major Depressive Disorder". Pharmaceutical Medicine. 27 (1): 35–42. 2013. doi:10.1007/s40290-013-0007-5. ISSN 1178-2595. 
  2. ^ http://www.fabrekramer.com/?page_id=66
  3. ^ http://adisinsight.springer.com/drugs/800029513

External links[edit]



Retrieved from "https://en.wikipedia.org/w/index.php?title=TGBA01AD&oldid=746234262"